JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Francis, H P
Right arrow Articles by Coxon, E A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Francis, H P
Right arrow Articles by Coxon, E A
Journal of Neurology Neurosurgery and Psychiatry 2004;75:1547-1551
© 2004 BMJ Publishing Group Ltd


PAPER

Does reducing spasticity translate into functional benefit? An exploratory meta-analysis

H P Francis1, D T Wade2, L Turner-Stokes3, R S Kingswell1, C S Dott1, E A Coxon1

1 Ipsen, 190 Bath Road, Slough, SL1 3XE, UK
2 Oxford Chair for Enablement, Windmill Road, Oxford, OX3 7LD, UK
3 Herbert Dunhill Chair of Rehabilitation, King‘s College, London, UK

Correspondence to:
Correspondence to:
Dr H Francis
Ipsen Limited, 190 Bath Road, Slough, SL1 3XE, Berkshire, UK; hilary.francis{at}ipsen.com

Background: Spasticity and loss of function in an affected arm are common after stroke. Although botulinum toxin is used to reduce spasticity, its functional benefits are less easily demonstrated. This paper reports an exploratory meta-analysis to investigate the relationship between reduced arm spasticity and improved arm function.

Method: Individual data from stroke patients in two randomised controlled trials of intra-muscular botulinum toxin were pooled. The Modified Ashworth Scale (elbow, wrist, fingers) was used to calculate a "Composite Spasticity Index". Data from the arm section of the Barthel Activities of Daily Living Index (dressing, grooming, and feeding) and three subjective measures (putting arm through sleeve, cleaning palm, cutting fingernails) were summed to give a "Composite Functional Index". Change scores and the time of maximum change were also calculated.

Results: Maximum changes in both composite measures occurred concurrently in 47 patients. In 26 patients the improvement in spasticity preceded the improvement in function with 18 showing the reverse. There was a definite relationship between the maximum change in spasticity and the maximum change in arm function, independent of treatment ({rho} = –0.2822, p = 0.0008, n = 137). There was a clear relationship between the changes in spasticity and in arm function in patients treated with botulinum toxin (Dysport) at 500 or 1000 units ({rho} = –0.5679, p = 0.0090, n = 22; {rho} = –0.4430, p = 0.0018, n = 47), but not in those treated with placebo or 1500 units.

Conclusions: Using a targeted meta-analytic approach, it is possible to demonstrate that reducing spasticity in the arm is associated with a significant improvement in arm function.


Abbreviations: ADL, activities of daily living; MAS, Modified Ashworth Scale

Keywords: arm; botulinum toxin; functional gain; outcome; spasticity




This article has been cited by other articles:


Home page
Clin Med ResHome page
S. Ozcakir and K. Sivrioglu
Botulinum Toxin in Poststroke Spasticity
Clin. Med. Res., June 1, 2007; 5(2): 132 - 138.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.